146 related articles for article (PubMed ID: 17962995)
1. Photodynamic therapy of the canine prostate: intra-arterial drug delivery.
Moore RB; Xiao Z; Owen RJ; Ashforth R; Dickey D; Helps C; Tulip J
Cardiovasc Intervent Radiol; 2008; 31(1):164-76. PubMed ID: 17962995
[TBL] [Abstract][Full Text] [Related]
2. Interstitial photodynamic therapy of the canine prostate using intra-arterial administration of photosensitizer and computerized pulsed light delivery.
Xiao Z; Dickey D; Owen RJ; Tulip J; Moore R
J Urol; 2007 Jul; 178(1):308-13. PubMed ID: 17499802
[TBL] [Abstract][Full Text] [Related]
3. Prostate perfusion mapped by technetium-99m macroaggregated albumin after selective arterial injection.
Abele JT; Moore R; Tymchak W; Owen RJ
J Vasc Interv Radiol; 2015 Mar; 26(3):418-25. PubMed ID: 25636669
[TBL] [Abstract][Full Text] [Related]
4. Lipophilic photosensitizer administration via the prostate arteries for photodynamic therapy of the canine prostate.
Xiao Z; Owen RJ; Liu W; Tulip J; Brown K; Woo T; Moore RB
Photodiagnosis Photodyn Ther; 2010 Jun; 7(2):106-14. PubMed ID: 20510305
[TBL] [Abstract][Full Text] [Related]
5. Photodynamic therapy of intracranial tissues: a preclinical comparative study of four different photosensitizers.
Lilge L; Wilson BC
J Clin Laser Med Surg; 1998 Apr; 16(2):81-91. PubMed ID: 9663099
[TBL] [Abstract][Full Text] [Related]
6. Prediction of myocutaneous adverse side effect due to intra-arterial chemotherapy by intra-arterial (99m)Tc-macroaggregated albumin administration in patients with bone and soft-tissue tumors.
Taki J; Sumiya H; Higuchi T; Tsuchiya H; Takazawa K; Tomita K; Tonami N
J Nucl Med; 2002 Nov; 43(11):1452-6. PubMed ID: 12411547
[TBL] [Abstract][Full Text] [Related]
7. Preclinical studies in normal canine prostate of a novel palladium-bacteriopheophorbide (WST09) photosensitizer for photodynamic therapy of prostate cancers.
Chen Q; Huang Z; Luck D; Beckers J; Brun PH; Wilson BC; Scherz A; Salomon Y; Hetzel FW
Photochem Photobiol; 2002 Oct; 76(4):438-45. PubMed ID: 12405153
[TBL] [Abstract][Full Text] [Related]
8. Spatial distribution of liposome encapsulated tin etiopurpurin dichloride (SnET2) in the canine prostate: implications for computer simulation of photodynamic therapy.
Aniola J; Selman SH; Lilge L; Keck R; Jankun J
Int J Mol Med; 2003 Mar; 11(3):287-91. PubMed ID: 12579328
[TBL] [Abstract][Full Text] [Related]
9. Photodynamic therapy in the canine prostate using motexafin lutetium.
Hsi RA; Kapatkin A; Strandberg J; Zhu T; Vulcan T; Solonenko M; Rodriguez C; Chang J; Saunders M; Mason N; Hahn S
Clin Cancer Res; 2001 Mar; 7(3):651-60. PubMed ID: 11297261
[TBL] [Abstract][Full Text] [Related]
10. Studies of a vascular-acting photosensitizer, Pd-bacteriopheophorbide (Tookad), in normal canine prostate and spontaneous canine prostate cancer.
Huang Z; Chen Q; Luck D; Beckers J; Wilson BC; Trncic N; Larue SM; Blanc D; Hetzel FW
Lasers Surg Med; 2005 Jun; 36(5):390-7. PubMed ID: 15856509
[TBL] [Abstract][Full Text] [Related]
11. Combining vascular and cellular targeting regimens enhances the efficacy of photodynamic therapy.
Chen B; Pogue BW; Hoopes PJ; Hasan T
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1216-26. PubMed ID: 15752904
[TBL] [Abstract][Full Text] [Related]
12. Photodynamic therapy with motexafin lutetium for rectal cancer: a preclinical model in the dog.
Ross HM; Smelstoys JA; Davis GJ; Kapatkin AS; Del Piero F; Reineke E; Wang H; Zhu TC; Busch TM; Yodh AG; Hahn SM
J Surg Res; 2006 Oct; 135(2):323-30. PubMed ID: 16650871
[TBL] [Abstract][Full Text] [Related]
13. Zinc phthalocyanine tetrasulfonate (ZnPcS4): a new photosensitizer for photodynamic therapy in choroidal neovascularization.
Huang Y; Xu G; Peng Y; Lin H; Zheng X; Xie M
J Ocul Pharmacol Ther; 2007 Aug; 23(4):377-86. PubMed ID: 17803437
[TBL] [Abstract][Full Text] [Related]
14. Interstitial photodynamic therapy in the canine prostate with disulfonated aluminum phthalocyanine and 5-aminolevulinic acid-induced protoporphyrin IX.
Chang SC; Buonaccorsi GA; MacRobert AJ; Bown SG
Prostate; 1997 Jul; 32(2):89-98. PubMed ID: 9215396
[TBL] [Abstract][Full Text] [Related]
15. Studies of tin ethyl etiopurpurin photodynamic therapy of the canine prostate.
Selman SH; Albrecht D; Keck RW; Brennan P; Kondo S
J Urol; 2001 May; 165(5):1795-801. PubMed ID: 11342978
[TBL] [Abstract][Full Text] [Related]
16. Targeting tumor vasculature and cancer cells in orthotopic breast tumor by fractionated photosensitizer dosing photodynamic therapy.
Dolmans DE; Kadambi A; Hill JS; Flores KR; Gerber JN; Walker JP; Borel Rinkes IH; Jain RK; Fukumura D
Cancer Res; 2002 Aug; 62(15):4289-94. PubMed ID: 12154031
[TBL] [Abstract][Full Text] [Related]
17. Interstitial and transurethral photodynamic therapy of the canine prostate using meso-tetra-(m-hydroxyphenyl) chlorin.
Chang SC; Buonaccorsi G; MacRobert A; Bown SG
Int J Cancer; 1996 Aug; 67(4):555-62. PubMed ID: 8759616
[TBL] [Abstract][Full Text] [Related]
18. Pretreatment photosensitizer dosimetry reduces variation in tumor response.
Zhou X; Pogue BW; Chen B; Demidenko E; Joshi R; Hoopes J; Hasan T
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1211-20. PubMed ID: 16504761
[TBL] [Abstract][Full Text] [Related]
19. Targeted in vivo photodynamic therapy with epidermal growth factor receptor-specific peptide linked nanoparticles.
Narsireddy A; Vijayashree K; Irudayaraj J; Manorama SV; Rao NM
Int J Pharm; 2014 Aug; 471(1-2):421-9. PubMed ID: 24939618
[TBL] [Abstract][Full Text] [Related]
20. A delivery system to avoid self-aggregation and to improve in vitro and in vivo skin delivery of a phthalocyanine derivative used in the photodynamic therapy.
Rossetti FC; Lopes LB; Carollo AR; Thomazini JA; Tedesco AC; Bentley MV
J Control Release; 2011 Nov; 155(3):400-8. PubMed ID: 21763732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
